Original news and analysis on international IP policy
A United Nations high-level panel of experts has set a process in motion to find solutions to increase access to medicines. Following its first meeting last week, the panel will call for proposals to recommend solutions that can promote innovation, but preserve human rights and public health interests.
America’s International Trade Commission is a tempting venue for US intellectual property owners. The agency acts quickly, has a history of supporting IP owners, and offers a powerful means to stop infringing products from entering the US. So when the ITC expanded its jurisdiction last year, claiming the power to stop online infringements, many IP owners cheered. And many internet companies fretted. Until last month, when the Federal Circuit had its say.
Two and a half years after an international treaty was adopted to facilitate access to special format literary works for blind and visually impaired people, the European Blind Union blames the failure of the European Union to ratify it as a failure to implement the right to read in the EU.
Colombia has a decision to make. A full year has passed from the November 24, 2014 request by iFarma, Misión Salud and CIMUN for a declaration of the public interest regarding the cancer drug imatinib (marketed by Novartis as Gleevec/Glivec), the first step on the path toward a compulsory license in Colombia. Thus far, Colombia’s Ministry of Health and Social Protection has failed to act one way or another, leaving patients in limbo and the government at the mercy of a Swiss pharmaceutical giant that reported revenue of over $57.9 Billion USD in 2013, write James Love and Andrew S. Goldman.
The United Nations Development Programme joined forces with the World Blind Union to prepare a new report aimed at facilitating Asia-Pacific countries’ ratification of a treaty designed to help visually-impaired people access special format books.
For the first time in its history, the G10 Commission, an oversight body over the German Intelligence Services, will go to court to challenge decisions by the German government and the services, German Public Broadcasting and the Süddeutsche Zeitung revealed last night.
Ten sites allegedly disrespectful to Kemal Attaturk, founder of modern Turkey, were enough for the courts in Turkey to ban a whole platform - YouTube - from 2008 until the end of 2010. But a ruling of the European Court of Human Rights today declared the blanket blocking a violation of the right to receive and impart information freely, protected under Article 10 of the European Convention on Human Rights.
Two bipartisan United States senators today released the results of an 18-month investigation into the US$84,000 price of the Sovaldi hepatitis C drug, finding the pricing and marketing strategy was aimed at maximizing revenue at the expense of access and affordability. The new report also shows the high impact on US government drug procurement programs and other data.
Alongside this week's meeting of the World Intellectual Property Organization committee on enforcement, an event featured a former South African Supreme Court judge presenting his views on IP enforcement. There is a need to go for the “big fish,” he said, and to bring balance in sanctions and enforcement procedures. He also described courts as finding that exceptions to copyright are a public right.
South American countries are negotiating with pharmaceutical companies to obtain common cheaper prices for high-cost medicines. The first target of initial negotiations delivered lower prices for hepatitis C and HIV. Further negotiations will be geared to additional hepatitis C, HIV and oncology medicines.
Saying she could speak more freely outside of the World Health Organization, WHO Director General Margaret Chan today told a gathering of think tank representatives at the Graduate Institute of Geneva that intellectual property rights may be unfairly driving up drug prices and that industry lobbying may be interfering with governments' efforts to take action on behalf of their citizens' public health.
Last week's decision by a World Trade Organization committee to allow least-developed countries to not apply global IP rules for pharmaceuticals for 17 more years made WTO members accountable to humanity, the coordinator of the LDC Group has said. Pharmaceuticals are different from all other forms of IP, he said.